Takeaways: Rhapsido gives Canadian clinicians a first-in-class, oral BTK inhibitor option for CSU patients who are still symptomatic on H1 antihistamines, adding a targeted,...
Browsing Tag: Phase III REMIX-2
Takeaways: Rhapsido gives Canadian clinicians a first-in-class, oral BTK inhibitor option for CSU patients who are still symptomatic on H1 antihistamines, adding a targeted,...